CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 25, 2026
Multiple CAR-T Cell Therapy Targeting AML
(clinicaltrials.gov)
- P1/2 | N=10 | Terminated | Sponsor: Shenzhen Geno-Immune Medical Institute | Recruiting ➔ Terminated | Trial primary completion date: Jul 2028 ➔ Jul 2026 | Trial completion date: Dec 2029 ➔ Jul 2026
Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • IL3RA
April 25, 2026
Multiple CAR-T Cell Therapy Targeting AML
(clinicaltrials.gov)
- P1/2 | N=10 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 ➔ Dec 2029 | Trial primary completion date: Jul 2021 ➔ Jul 2028
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • IL3RA
1 to 2
Of
2
Go to page
1